Patent · US Active

Pyrrolo and pyrazolopyrimidines as ubiquitin-specific protease 7 inhibitors

US10377760B2 · kind B2 · utility

15Cited by

65References

20Claims

0Family size

Assignee

FORMA Therapeutics, Inc. · US

Inventors

Stephanos Ioannidis · Natick, US
Adam Charles Talbot · Guilford, US
Bruce Follows · Littleton, US
Alexandre Joseph Buckmelter · Superior, US
Minghua Wang · Acton, US
Ann-Marie Campbell · Monroe, US
Darby Schmidt · Arlington, US
David Joseph Guerin · Natick, US
Justin Andrew Caravella · Cambridge, US
R. Bruce Diebold · Waltham, US
Anna Ericsson · Keyano, CA
David R. Lancia, Jr. · Boston, US

Key dates

Filing date	Jan 18, 2018
Grant date	Aug 13, 2019
Priority date	—
Expiry date	Jan 18, 2038

Classification

Technology area (CPC Y)Emerging Cross-Sectional Technologies
CPC primaryY02A50/30
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The invention relates to inhibitors of USP7 inhibitors useful in the treatment of cancers, neurodegenerative diseases, immunological disorders, inflammatory disorders, cardiovascular diseases, ischemic diseases, viral infections and diseases, and bacterial infections and diseases, having the Formula: where m, n, X1, X2, R1-R5, R5 and R6 are described herein.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.